Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 2/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556468 | 0.89 | CCR2 (0.34) | CCR2CNR2DRD2MC4RRORC | |
| SCHEMBL556119 | 0.81 | CNR2 (0.34) | CCR2CNR2DRD2MC4RSLC6A3 | |
| SCHEMBL556679 | 0.81 | CNR2 (0.35) | CCR2CNR2DRD2MC4RSLC6A3 | |
| SCHEMBL2430891 | 0.80 | CCR2 (0.38) | CCR2CNR2DRD2MC4RSLC6A3 | |
| SCHEMBL555701 | 0.78 | SLC6A2 (0.33) | CCR2CNR2DRD2MC4RSLC6A3 | |
| SCHEMBL534534 | 0.75 | OPRD1 (0.36) | CCR2MC4RRORCSLC6A3KMT2A | |
| SCHEMBL535063 | 0.74 | DRD2 (0.39) | CCR2DRD2 | |
| SCHEMBL4926309 | 0.72 | SLC6A3 (0.45) | CNR2DRD2RORCSLC6A3KMT2A | |
| SCHEMBL4919417 | 0.72 | SLC6A3 (0.45) | CNR2DRD2RORCSLC6A3KMT2A | |
| SCHEMBL557090 | 0.71 | RORC (0.39) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | CCR2 1104/4885CNR2 2092/4885DRD2 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.